ARS Pharmaceuticals (SPRY) Competitors

ARS Pharmaceuticals (NASDAQ:SPRY) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

Do analysts recommend SPRY or ACAD?

ARS Pharmaceuticals currently has a consensus target price of $32.50, indicating a potential upside of 225.81%. ACADIA Pharmaceuticals has a consensus target price of $29.65, indicating a potential upside of 22.21%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe ARS Pharmaceuticals is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
ACADIA Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.63

Is SPRY or ACAD more profitable?

ACADIA Pharmaceuticals has a net margin of 21.80% compared to ARS Pharmaceuticals' net margin of -42.74%. ACADIA Pharmaceuticals' return on equity of 14.69% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-42.74%	-21.85%	-15.88%
ACADIA Pharmaceuticals	21.80%	14.69%	9.41%

Do institutionals & insiders believe in SPRY or ACAD?

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 33.5% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the media favor SPRY or ACAD?

In the previous week, ACADIA Pharmaceuticals had 17 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 25 mentions for ACADIA Pharmaceuticals and 8 mentions for ARS Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.93 beat ARS Pharmaceuticals' score of 0.68 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	12 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, SPRY or ACAD?

ARS Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.

Which has higher valuation and earnings, SPRY or ACAD?

ACADIA Pharmaceuticals has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$112.34M	8.78	$8M	-$0.49	-20.36
ACADIA Pharmaceuticals	$957.80M	4.27	$226.45M	$1.33	18.24

Summary

ACADIA Pharmaceuticals beats ARS Pharmaceuticals on 11 of the 16 factors compared between the two stocks.